The KCTD6 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for the disruption of the human KCTD6 gene in HeLa cells. This product provides a heterogeneous pool of edited cells carrying diverse loss-of-function mutations, enabling robust functional interrogation of KCTD6 without the clonal biases inherent in single-cell-derived lines. The polyclonal format is particularly suited for pooled screening and population-level analyses, offering a representative model of gene disruption across the cell population.
The host HeLa cell line is an immortalized epithelial cell line derived from a human cervical adenocarcinoma, widely employed as a workhorse in cancer cell biology and signal transduction research. These cells are positive for human papillomavirus type 18 (HPV-18) and exhibit a highly aneuploid karyotype, reflecting genomic instability typical of many aggressive carcinomas. The HeLa background provides a well-characterized platform for studying oncogenic mechanisms, tumor suppressor pathways, and the ubiquitin-proteasome system in a cervical cancer context.
KCTD6 functions as a substrate adaptor for the Cullin3-RING E3 ubiquitin ligase (CRL3) complex, interacting with Cullin-3 (CUL3) and RING-box protein 1 (RBX1) to mediate ubiquitination and proteasomal degradation of target proteins, notably HDAC1 and Twist1. Through this, KCTD6 modulates Wnt/??-catenin signaling by controlling Twist1 stability, which influences ??-catenin/TCF transcriptional activity and downstream targets such as cyclin D1, and intersects with the EGFR pathway, where EGF stimulation and downstream PI3K-AKT-GSK3?? signaling converge on ??-catenin. By targeting HDAC1 for degradation, KCTD6 also impacts chromatin remodeling and gene expression. Thus, KCTD6 links ubiquitin-mediated proteolysis to cellular proliferation, migration, and invasion.
In the HeLa cellular context, disruption of KCTD6 can dysregulate the balance of oncogenic and tumor-suppressive signals. As cervical cancer cells often exhibit altered ubiquitin-proteasome activity and aberrant Wnt/EGFR crosstalk, KCTD6 knockout provides a relevant model to dissect how CRL3-mediated degradation controls cancer cell behavior. This model is also pertinent for investigating molecular mechanisms associated with neurodevelopmental disorders, given the implication of KCTD6 and its interacting partners in schizophrenia and autism spectrum disorder. The polyclonal knockout population permits the study of KCTD6-dependent phenotypes at a population level, mitigating artifacts from individual clonal selection.
Researchers can employ these knockout cells in functional assays including western blotting, cell proliferation and colony formation assays, and Transwell migration/invasion assays to assess KCTD6-dependent phenotypes. Ubiquitination assays and co-immunoprecipitation can elucidate changes in substrate modification and complex formation, while RNA-seq enables transcriptome-wide profiling. The cells are suitable for target validation in oncogenic pathways and for screening proteolysis-targeting chimeras (PROTACs). For further details, please contact Ascent Research.
